目次

Table of Contents

1 Introduction
1.1. What is this report about?
1.2. Who is the target reader?
1.3. How to use this report
1.4. Definitions

2 NAFTA Generics
2.1. Industry Outlook

3 Generics in Canada
3.1. Market Overview
3.2. Market Data
3.3. Market Segmentation
3.4. Market outlook
3.5. Five forces analysis

4 Macroeconomic Indicators
4.1. Country data

5 Generics in Mexico
5.1. Market Overview
5.2. Market Data
5.3. Market Segmentation
5.4. Market outlook
5.5. Five forces analysis

6 Macroeconomic Indicators
6.1. Country data

7 Generics in The United States
7.1. Market Overview
7.2. Market Data
7.3. Market Segmentation
7.4. Market outlook
7.5. Five forces analysis

8 Macroeconomic Indicators
8.1. Country data

9 Company Profiles
9.1. Teva Pharmaceutical Industries Ltd
9.2. Viatris Inc
9.3. Sun Pharmaceutical Industries Ltd
9.4. Novartis AG
9.5. Sandoz Group AG
9.6. Hikma Pharmaceuticals Plc
9.7. Sanofi
9.8. Les Laboratoires Servier SAS
9.9. Stada Arzneimittel AG
9.10. Bayer AG
9.11. Lupin Ltd
9.12. Aspen Pharmacare Holdings Ltd
9.13. EMS SA
9.14. Eurofarma Laboratorios SA
9.15. Ache Laboratorios Farmaceuticos SA
9.16. Apotex Inc
9.17. Teva Canada Ltd
9.18. Sandoz Canada Inc
9.19. CSPC Pharmaceutical Group Ltd
9.20. Sino Biopharmaceutical Ltd
9.21. Hansoh Pharmaceutical Group Co Ltd
9.22. Dr. Reddy's Laboratories Ltd
9.23. Cipla Ltd
9.24. Aurobindo Pharma Ltd
9.25. PT Kalbe Farma Tbk
9.26. PT Indofarma Tbk
9.27. PT Sanbe Farma
9.28. PT Soho Global Health Tbk
9.29. Friulchem SpA
9.30. DOC Generici SRL
9.31. Recordati SpA
9.32. Daiichi Sankyo Co Ltd
9.33. Towa Pharmaceutical Co Ltd
9.34. Sawai Group Holdings Co Ltd
9.35. Toho Holdings Co Ltd
9.36. Laboratorios Silanes SA de CV
9.37. Pfizer Inc
9.38. Biocad
9.39. R-Pharm
9.40. Pharmstandard
9.41. AstraZeneca Plc
9.42. Bluefish Pharmaceuticals AB
9.43. Navamedic ASA
9.44. Novartis International AG
9.45. Beacons Pharmaceuticals Pte Ltd
9.46. Abbott Laboratories SA
9.47. Adcock Ingram Holdings Ltd
9.48. Dongkook Pharmaceutical Co Ltd
9.49. JW Holdings Corp
9.50. Hanmi Pharmaceuticals Co Ltd
9.51. Dong Wha Pharma Co Ltd
9.52. Esteve Pharmaceuticals SA
9.53. Abdi Ibrahim Ilac Sanayi ve Ticaret AS
9.54. Deva Holding AS
9.55. Sandoz Inc

10 Appendix
10.1. Methodology
10.2. About MarketLine

List of Tables
Table 1: NAFTA countries generics industry, revenue ($m), 2019-28
Table 2: NAFTA countries generics industry, revenue ($m), 2019-23
Table 3: NAFTA countries generics industry forecast, revenue ($m), 2023-28
Table 4: Canada generics market value: $ million, 2018-23
Table 5: Canada generics market volume: % of total pharma volume, 2018-23
Table 6: Canada generics market geography segmentation: $ million, 2023
Table 7: Canada generics market value forecast: $ million, 2023-28
Table 8: Canada generics market volume forecast: % of total pharma volume, 2023-28
Table 9: Canada Size of Population (million), 2019-23
Table 10: Canada real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 11: Canada GDP (Current Prices, $ Billion), 2019-23
Table 12: Canada Inflation, 2019-23
Table 13: Canada Consumer Price Index (Absolute), 2019-23
Table 14: Canada exchange rate, 2018-23
Table 15: Mexico generics market value: $ million, 2018-23
Table 16: Mexico generics market volume: % of total pharma volume, 2018-23
Table 17: Mexico generics market geography segmentation: $ million, 2023
Table 18: Mexico generics market value forecast: $ million, 2023-28
Table 19: Mexico generics market volume forecast: % of total pharma volume, 2023-28
Table 20: Mexico Size of Population (million), 2019-23
Table 21: Mexico real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 22: Mexico GDP (Current Prices, $ Billion), 2019-23
Table 23: Mexico Inflation, 2019-23
Table 24: Mexico Consumer Price Index (Absolute), 2019-23
Table 25: Mexico exchange rate, 2018-23
Table 26: United States generics market value: $ million, 2018-23
Table 27: United States generics market volume: % of total pharma volume, 2018-23
Table 28: United States generics market geography segmentation: $ million, 2023
Table 29: United States generics market value forecast: $ million, 2023-28
Table 30: United States generics market volume forecast: % of total pharma volume, 2023-28
Table 31: United States Size of Population (million), 2019-23
Table 32: United States real GDP (Constant 2010 Prices, $ billion), 2019-23
Table 33: United States GDP (Current Prices, $ Billion), 2019-23
Table 34: United States Inflation, 2019-23
Table 35: United States Consumer Price Index (Absolute), 2019-23
Table 36: United States exchange rate, 2018-23
Table 37: Teva Pharmaceutical Industries Ltd: key facts
Table 38: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 39: Teva Pharmaceutical Industries Ltd: Key Employees
Table 40: Viatris Inc: key facts
Table 41: Viatris Inc: Annual Financial Ratios
Table 42: Viatris Inc: Key Employees
Table 43: Sun Pharmaceutical Industries Ltd: key facts
Table 44: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 45: Sun Pharmaceutical Industries Ltd: Key Employees
Table 46: Novartis AG: key facts
Table 47: Novartis AG: Annual Financial Ratios
Table 48: Novartis AG: Key Employees
Table 49: Sandoz Group AG: key facts
Table 50: Sandoz Group AG: Key Employees
Table 51: Hikma Pharmaceuticals Plc: key facts
Table 52: Hikma Pharmaceuticals Plc: Annual Financial Ratios
Table 53: Hikma Pharmaceuticals Plc: Key Employees
Table 54: Sanofi: key facts
Table 55: Sanofi: Annual Financial Ratios
Table 56: Sanofi: Key Employees
Table 57: Les Laboratoires Servier SAS: key facts
Table 58: Les Laboratoires Servier SAS: Key Employees
Table 59: Stada Arzneimittel AG: key facts
Table 60: Stada Arzneimittel AG: Key Employees
Table 61: Bayer AG: key facts
Table 62: Bayer AG: Annual Financial Ratios
Table 63: Bayer AG: Key Employees
Table 64: Bayer AG: Key Employees Continued
Table 65: Bayer AG: Key Employees Continued
Table 66: Lupin Ltd: key facts
Table 67: Lupin Ltd: Annual Financial Ratios
Table 68: Lupin Ltd: Key Employees
Table 69: Aspen Pharmacare Holdings Ltd: key facts
Table 70: Aspen Pharmacare Holdings Ltd: Annual Financial Ratios
Table 71: Aspen Pharmacare Holdings Ltd: Key Employees
Table 72: EMS SA: key facts
Table 73: EMS SA: Key Employees
Table 74: Eurofarma Laboratorios SA: key facts
Table 75: Eurofarma Laboratorios SA: Key Employees
Table 76: Ache Laboratorios Farmaceuticos SA: key facts
Table 77: Ache Laboratorios Farmaceuticos SA: Key Employees
Table 78: Apotex Inc: key facts
Table 79: Apotex Inc: Key Employees
Table 80: Teva Canada Ltd: key facts
Table 81: Teva Canada Ltd: Key Employees
Table 82: Sandoz Canada Inc: key facts
Table 83: Sandoz Canada Inc: Key Employees
Table 84: CSPC Pharmaceutical Group Ltd: key facts
Table 85: CSPC Pharmaceutical Group Ltd: Annual Financial Ratios
Table 86: CSPC Pharmaceutical Group Ltd: Key Employees
Table 87: Sino Biopharmaceutical Ltd: key facts
Table 88: Sino Biopharmaceutical Ltd: Annual Financial Ratios
Table 89: Sino Biopharmaceutical Ltd: Key Employees
Table 90: Hansoh Pharmaceutical Group Co Ltd: key facts
Table 91: Hansoh Pharmaceutical Group Co Ltd: Annual Financial Ratios
Table 92: Dr. Reddy's Laboratories Ltd: key facts
Table 93: Dr. Reddy's Laboratories Ltd: Annual Financial Ratios
Table 94: Dr. Reddy's Laboratories Ltd: Key Employees

List of Figures
Figure 1: NAFTA countries generics industry, revenue ($m), 2019-28
Figure 2: NAFTA countries generics industry, revenue ($m), 2019-23
Figure 3: NAFTA countries generics industry forecast, revenue ($m), 2023-28
Figure 4: Canada generics market value: $ million, 2018-23
Figure 5: Canada generics market volume: % of total pharma volume, 2018-23
Figure 6: Canada generics market geography segmentation: % share, by value, 2023
Figure 7: Canada generics market value forecast: $ million, 2023-28
Figure 8: Canada generics market volume forecast: % of total pharma volume, 2023-28
Figure 9: Forces driving competition in the generics market in Canada, 2023
Figure 10: Drivers of buyer power in the generics market in Canada, 2023
Figure 11: Drivers of supplier power in the generics market in Canada, 2023
Figure 12: Factors influencing the likelihood of new entrants in the generics market in Canada, 2023
Figure 13: Factors influencing the threat of substitutes in the generics market in Canada, 2023
Figure 14: Drivers of degree of rivalry in the generics market in Canada, 2023
Figure 15: Mexico generics market value: $ million, 2018-23
Figure 16: Mexico generics market volume: % of total pharma volume, 2018-23
Figure 17: Mexico generics market geography segmentation: % share, by value, 2023
Figure 18: Mexico generics market value forecast: $ million, 2023-28
Figure 19: Mexico generics market volume forecast: % of total pharma volume, 2023-28
Figure 20: Forces driving competition in the generics market in Mexico, 2023
Figure 21: Drivers of buyer power in the generics market in Mexico, 2023
Figure 22: Drivers of supplier power in the generics market in Mexico, 2023
Figure 23: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2023
Figure 24: Factors influencing the threat of substitutes in the generics market in Mexico, 2023
Figure 25: Drivers of degree of rivalry in the generics market in Mexico, 2023
Figure 26: United States generics market value: $ million, 2018-23
Figure 27: United States generics market volume: % of total pharma volume, 2018-23
Figure 28: United States generics market geography segmentation: % share, by value, 2023
Figure 29: United States generics market value forecast: $ million, 2023-28
Figure 30: United States generics market volume forecast: % of total pharma volume, 2023-28
Figure 31: Forces driving competition in the generics market in the United States, 2023
Figure 32: Drivers of buyer power in the generics market in the United States, 2023
Figure 33: Drivers of supplier power in the generics market in the United States, 2023
Figure 34: Factors influencing the likelihood of new entrants in the generics market in the United States, 2023
Figure 35: Factors influencing the threat of substitutes in the generics market in the United States, 2023
Figure 36: Drivers of degree of rivalry in the generics market in the United States, 2023